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Abstract 
An elevated serum CA125 level in association with a pelvic mass, pleural effusion, and 
massive ascites usually signifies a dismal prognosis in a postmenopausal woman. 
However, surgery and histopathological examination are required for the correct 
diagnosis and treatment, since an elevated CA125 level can be falsely positive for ovarian 
malignancy. We present a case of Meigs’ syndrome due to right ovarian fibroma with 
elevated CA125 level in a postmenopausal woman. 
 
Introduction 
The importance of ovarian cancer stems not from the fact that it is the sixth most 
common cancer in women worldwide, but from the fact that it is the most lethal 
gynecologic malignancy in Western Europe and North America, killing more women 
than uterine and cervical cancer combined. It is predominantly a disease of 
postmenopausal women, with a median age at diagnosis of 60 years [1]. Elevated serum 
CA125 levels in postmenopausal women with solid adnexal masses, ascites, and pleural 
effusion are highly suggestive for malignant ovarian tumor. However, surgery and 
histological confirmation of the preoperative diagnosis are mandatory, since a minority of 
patients with these findings have a benign condition, commonly known as Meigs’ 
syndrome. This condition disappears after removal of the pelvic tumor. We report a case 
of Meigs’ syndrome caused by right ovarian fibroma with elevated serum CA125 level in a 
postmenopausal woman.  
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Case Report 
A 56-year-old Thai woman was admitted to another hospital because of progressive dyspnea, 
abdominal distention and weight loss for 8 months. Her obstetric history included 3 uncomplicated 
deliveries. She had a history of diabetes mellitus since the age of 46 and her menopause occurred at the 
age of 52 years. The patient did not complain of any pain or changes in micturition or bowel habits. Her 
mother had died from endometrial cancer and her sister had a history of breast cancer. Marked right 
pleural effusion, ascites, and a large abdominal mass were found. Thoracocentesis was done to relieve 
her dyspnea. The cytology revealed atypical cells suggestive of malignancy. The patient was then 
referred to our hospital. 
On physical examination, there was dullness to percussion with decreased breath sounds in the half 
of the right lung field. Abdominal examination revealed shifting dullness and a palpable mass reaching 
to the umbilicus. On pelvic examination, a hard nodular 14 × 12 cm mass was palpated; a separate 
uterus could not be discerned. 
Ultrasonography of the abdomen and pelvis confirmed a moderate amount of ascites, the uterus 
appeared normal and a right adnexal solid mass of 14 × 12 cm was found. A chest X-ray revealed the 
presence of a massive right-sided and a minimal left-sided pleural effusion. Repeat thoracocentesis of 
right lung yielded 1,500 ml of fluid containing reactive mesothelial cells without evidence of malignancy 
noted on cytology review. Gram stain and acid fast stains also were reported as negative. Pleural biopsy 
was done and revealed non-specific chronic pleurisy. Blood chemistry was within normal limits except 
for a serum CA125 level of 1,064 U/ml (normal range 0–35 U/ml). 
Due to clinical suspicion of malignant ovarian tumor, the patient was submitted to exploratory 
laparotomy which revealed 2,500 ml of serous ascites. After aspiration of the ascitic fluid, a 13 × 10 × 10-
cm lobulated right adnexal solid mass without excrescences was found (fig. 1). The uterus and left 
adnexa appeared normal. Frozen section of the right adnexal mass was read as benign ovarian fibroma. 
There was no palpable pelvic or periaortic adenopathy; the liver, diaphragm, bowel, and omentum were 
grossly free of disease. The patient subsequently underwent a total abdominal hysterectomy with 
bilateral salpingo-oophorectomy. Pathological examination of the specimen showed a benign fibroma of 
the right ovary. 
The postoperative period was uneventful and the patient was discharged on the seventh 
postoperative day. The serum CA125 level on the sixth postoperative day was 22 U/ml. Six weeks 
postoperatively, she was followed on an outpatient basis without further complaints. The pleural 
effusion was resolved completely on repeat chest X-ray. The patient was asymptomatic with a normal 
serum CA125 level 6 months after the operation. 
Discussion 
In 1934, Salmon described the association of pleural effusion with benign pelvic 
tumors. It was not until the report by Meigs and Cass in 1937 that widespread attention of 
the medical profession was drawn to the significance of pleural effusion and ascites in 
benign ovarian fibroma [2]. Meigs’ syndrome is defined as the triad of benign ovarian 
tumor with ascites and pleural effusion that resolves after resection of the tumor. 
Although Meigs’ syndrome mimics a malignant condition, it is a benign disease and has a 
very good prognosis if properly managed. Life expectancy after surgical removal of the 
tumor mirrors that of the general population. 
Ovarian fibroma is found in 2–5% of surgically removed ovarian tumors [3], and 
Meigs’ syndrome is observed in about 1% [4]. Ascites is present in 10–15% of those with 
ovarian fibroma and pleural effusion in 1%, especially with large lesion [5, 6]. 
The pathophysiology of ascites in Meigs’ syndrome is subject to debate and remains 
unclear. Meigs suggested that irritation of the peritoneal surfaces by a hard, solid ovarian 
tumor could stimulate the production of peritoneal fluid [7]. Other proposed mechanisms 
are direct pressure on surrounding lymphatics or vessels, hormonal stimulation, or 
release of mediators from the tumor, leading to increased capillary permeability [5, 8, 9].  
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The etiology of pleural effusion is unclear. It is thought that the occurrence of pleural 
effusion is secondary to the passage of ascitic fluid to the pleural space through the 
diaphragm or diaphragmatic lymph vessels which are more common on the right side 
[10]. The size of the pleural effusion is largely independent of the amount of ascites. The 
connection between the pelvic tumor and ascites is confirmed by the rapid resolution of 
abdominal and pleural fluid after removal of the tumor. 
CA125 antigen is a glycoprotein with a high molecular weight and is recognized by a 
monoclonal antibody (OC-125). It is expressed in the amnion and embryonic coelomic 
epithelium [11]. The antigen can also appear in many adult tissues such as the epithelium 
of the fallopian tubes, endometrium, endocervix, and ovaries [12]. In addition, it is found 
in mesothelial cells of the pleura, pericardium and peritoneum. Therefore, some normal 
body tissues can produce a certain and low level of circulatory or serum CA125. This 
tumor marker is found elevated during menstruation or pregnancy and in some benign 
conditions such as endometriosis, peritonitis or cirrhosis, particularly with ascites [13, 
14]. It is also increased in vascular invasion, tissue destruction and inflammation 
associated with malignant disease. In a series by O’Connell et al. [15], the predictive value 
of a CA125 level greater than 35 U/ml was 60% for ovarian cancer and 84% for some type 
of malignancy. The authors also reported three patients with ovarian fibroma and 
elevated serum CA125 levels (above 35 U/ml) in their series. No details were given 
whether these patients also had Meigs’ syndrome. 
The coincidence of Meigs’ syndrome with elevation of serum CA125 levels has been 
described in the published literature in only 28 cases (table 1). The histological types 
reported have been fibroma (15 cases), cellular fibroma (4 cases), thecoma (4 cases), 
fibroma thecoma (3 cases), granulosa cell tumor (1 case), and benign Brenner tumor (1 
case). Serum CA125 levels above 1,000 U/ml are exceptional, and only 6 cases with this 
feature have been reported previous to the present study. 
The immunohistochemical study for CA125 suggested that serum elevation of CA125 
antigen in patients with Meigs’ syndrome is caused by mesothelial expression of CA125 
rather than by fibroma [22, 25]. The precise mechanism remains unclear, but a 
biomedical factor, mechanical irritation from a large tumor, or an increase in 
intraperitoneal pressure from a large volume of ascites might be primary factors in this 
process. 
The association of massive abdominal ascites, pleural effusion, and a large pelvic mass 
with an elevated serum CA125 level portends a poor prognosis. However, it is paramount 
to remember that this combination of findings does not always predict an ominous 
diagnosis. This case illustrates the importance of appropriate surgery to obtain 
histopathological confirmation of Meigs’ syndrome, as a small percentage of patients will 
have a benign etiology even in the presence of an elevated serum CA125 level. 
 
 
  
Case Rep Oncol 2009;2:61–66 
DOI: 10.1159/000210441 
Published online: April 4, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
64
Table 1. Summary of reported cases of Meigs’ syndrome with elevated serum CA125 level 
Author Year  No.  of 
cases 
Age Histopathology  CA125 
U/ml 
Jones and Surwit [16]  1989 1  70  Fibroma/thecoma  226 
Hoffman [17]  1989  1  39  Thecoma  498 
Martin et al. [18]  1990  1  NR  Granulosa cell tumor  307 
Walker et al. [19]  1990  2  52, 67  Cellular fibroma  >5,000, 104 
Le Bouedec et al. [20]  1992  2  66, 76  Fibroma/thecoma  645, 286 
Williams et al. [21]  1992  1 74  Luteinized  thecoma  329 
Lin et al. [22]  1992  2  74, 72  Fibroma  2,120, 7,000 
Turan et al. [23]  1993  1  63  Thecoma  744 
Siddiqui and Toub [24]  1995  1 73  Cellular  fibroma 1,780 
Timmerman et al. [25]  1995  2  71, 73  Fibroma  484.5, 42.3 
Abad et al. [5]  1997  1  51  Cellular fibroma  577 
Chan et al. [6]  2000  1  13  Fibroma  970 
Patsner [26]  2000  6  62, 57, 52, 
60, 72, 58 
Fibroma 185,  850,  520, 
64, 1,200, 80 
Buttin et al. [27]  2001  1  67  Brenner tumor  759 
López et al. [28]  2002  2  78, 68  Fibroma  498, 265 
Vieira et al. [29]  2003  1  65  Thecoma  319 
Móran-Mendoza et al. [30]  2004 1  46  Fibroma  1,808 
Current report  2007  1  56  Fibroma  1,064 
 
 
 
 
Fig. 1. Right ovarian fibroma measuring 13 × 10 × 10 cm and weighing 690 g. 
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